143 related articles for article (PubMed ID: 32893953)
21. Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the International Society of Pediatric Oncology MMT95 study.
Oberlin O; Rey A; Sanchez de Toledo J; Martelli H; Jenney ME; Scopinaro M; Bergeron C; Merks JH; Bouvet N; Ellershaw C; Kelsey A; Spooner D; Stevens MC
J Clin Oncol; 2012 Jul; 30(20):2457-65. PubMed ID: 22665534
[TBL] [Abstract][Full Text] [Related]
22. Successful treatment of orbital rhabdomyosarcoma in two infants using chemotherapy alone.
Lackner H; Urban C
Med Pediatr Oncol; 1997 Jun; 28(6):463-4. PubMed ID: 9143395
[No Abstract] [Full Text] [Related]
23. Phase II study of vincristine, actinomycin-D, cyclophosphamide and irinotecan for patients with newly diagnosed low-risk subset B rhabdomyosarcoma: A study protocol.
Miyachi M; Tsuchiya K; Hosono A; Ogawa A; Koh K; Kikuta A; Hara J; Teramukai S; Hosoi H
Medicine (Baltimore); 2019 Dec; 98(52):e18344. PubMed ID: 31876708
[TBL] [Abstract][Full Text] [Related]
24. [Vincristine-induced unilateral ptosis: case report and review of the literature].
Batta B; Trechot F; Cloché V; George JL; Angioi K
J Fr Ophtalmol; 2013 Oct; 36(8):683-6. PubMed ID: 23896211
[TBL] [Abstract][Full Text] [Related]
25. Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas: pilot study for the upcoming European Rhabdomyosarcoma Protocol.
Casanova M; Ferrari A; Bisogno G; Merks JH; De Salvo GL; Meazza C; Tettoni K; Provenzi M; Mazzarino I; Carli M
Cancer; 2004 Oct; 101(7):1664-71. PubMed ID: 15378498
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of ifosfamide and doxorubicin given as a phase II "window" in children with newly diagnosed metastatic rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study Group.
Sandler E; Lyden E; Ruymann F; Maurer H; Wharam M; Parham D; Link M; Crist W
Med Pediatr Oncol; 2001 Nov; 37(5):442-8. PubMed ID: 11745872
[TBL] [Abstract][Full Text] [Related]
27. Ifosfamide and actinomycin-D, added in the induction phase to vincristine, cyclophosphamide and doxorubicin, improve histologic response and prognosis in patients with non metastatic Ewing's sarcoma of the extremity.
Ferrari S; Mercuri M; Rosito P; Mancini A; Barbieri E; Longhi A; Rimondini S; Cesari M; Ruggieri P; Di Liddo M; Bacci G
J Chemother; 1998 Dec; 10(6):484-91. PubMed ID: 9876058
[TBL] [Abstract][Full Text] [Related]
28. High-dose melphalan with autologous stem-cell rescue in metastatic rhabdomyosarcoma.
Carli M; Colombatti R; Oberlin O; Stevens M; Masiero L; Frascella E; Koscielniak E; Treuner J; Pinkerton CR
J Clin Oncol; 1999 Sep; 17(9):2796-803. PubMed ID: 10561355
[TBL] [Abstract][Full Text] [Related]
29. Rhabdomyosarcoma of the corpus of the uterus: a case report.
Scheidt P; Moerman PH; Vergote I
Eur J Gynaecol Oncol; 2000; 21(4):371-3. PubMed ID: 11055485
[TBL] [Abstract][Full Text] [Related]
30. Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
Hawkins DS; Chi YY; Anderson JR; Tian J; Arndt CAS; Bomgaars L; Donaldson SS; Hayes-Jordan A; Mascarenhas L; McCarville MB; McCune JS; McCowage G; Million L; Morris CD; Parham DM; Rodeberg DA; Rudzinski ER; Shnorhavorian M; Spunt SL; Skapek SX; Teot LA; Wolden S; Yock TI; Meyer WH
J Clin Oncol; 2018 Sep; 36(27):2770-2777. PubMed ID: 30091945
[TBL] [Abstract][Full Text] [Related]
31. The predictive value of initial cytostatic response in primary unresectable rhabdomyosarcoma in children.
Treuner J; Suder J; Keim M; Kaatsch P; Niethammer D
Acta Oncol; 1989; 28(1):67-72. PubMed ID: 2706134
[TBL] [Abstract][Full Text] [Related]
32. Treatment of children with nonmetastatic paratesticular rhabdomyosarcoma: results of the Malignant Mesenchymal Tumors studies (MMT 84 and MMT 89) of the International Society of Pediatric Oncology.
Stewart RJ; Martelli H; Oberlin O; Rey A; Bouvet N; Spicer RD; Godzinski J; Stevens MC;
J Clin Oncol; 2003 Mar; 21(5):793-8. PubMed ID: 12610176
[TBL] [Abstract][Full Text] [Related]
33. Ifosfamide-induced renal tubular defect.
Torres Valdivieso MJ; López Pérez J; Melero C; Vivanco JL; Muley R; Vara J
Med Pediatr Oncol; 1994; 22(2):144-6. PubMed ID: 7505048
[TBL] [Abstract][Full Text] [Related]
34. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group.
Meza JL; Anderson J; Pappo AS; Meyer WH;
J Clin Oncol; 2006 Aug; 24(24):3844-51. PubMed ID: 16921036
[TBL] [Abstract][Full Text] [Related]
35. [Rhabdomyosarcoma of the bladder: a case report].
Kobayashi H; Kido K; Koie T; Ohyanagi H
Gan To Kagaku Ryoho; 1996 Feb; 23(3):365-8. PubMed ID: 8712832
[TBL] [Abstract][Full Text] [Related]
36. Comparison of results of a pilot study of alternating vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide with IRS-IV in intermediate risk rhabdomyosarcoma: a report from the Children's Oncology Group.
Arndt CA; Hawkins DS; Meyer WH; Sencer SF; Neglia JP; Anderson JR
Pediatr Blood Cancer; 2008 Jan; 50(1):33-6. PubMed ID: 17091486
[TBL] [Abstract][Full Text] [Related]
37. Reduction of cyclophosphamide dose for patients with subset 2 low-risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Walterhouse DO; Pappo AS; Meza JL; Breneman JC; Hayes-Jordan A; Parham DM; Cripe TP; Anderson JR; Meyer WH; Hawkins DS
Cancer; 2017 Jun; 123(12):2368-2375. PubMed ID: 28211936
[TBL] [Abstract][Full Text] [Related]
38. Irreversible encephalopathy with ifosfamide/mesna.
Salloum E; Flamant F; Ghosn M; Taleb N; Akatchereian C
J Clin Oncol; 1987 Aug; 5(8):1303-4. PubMed ID: 3114437
[No Abstract] [Full Text] [Related]
39. Neoadjuvant chemotherapy for Ewing's sarcoma of bone: no benefit observed after adding ifosfamide and etoposide to vincristine, actinomycin, cyclophosphamide, and doxorubicin in the maintenance phase--results of two sequential studies.
Bacci G; Picci P; Ferrari S; Mercuri M; Brach del Prever A; Rosito P; Barbieri E; Tienghi A; Forni C
Cancer; 1998 Mar; 82(6):1174-83. PubMed ID: 9506366
[TBL] [Abstract][Full Text] [Related]
40. Outcomes in paediatric metastatic rhabdomyosarcoma: results of The International Society of Paediatric Oncology (SIOP) study MMT-98.
McDowell HP; Foot AB; Ellershaw C; Machin D; Giraud C; Bergeron C
Eur J Cancer; 2010 Jun; 46(9):1588-95. PubMed ID: 20338746
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
